A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults with Generalized Myasthenia Gravis

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523950-15-01

Enrollment

Registered

2026-05-29

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Myasthenia Gravis

Brief summary

Phase 2: Percent change in total immunoglobulin G (IgG) [Time Frame: Baseline and At Week 12], Phase 2 and LTE: Safety and tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

Interventions

DRUGTest IMP without active substance

DRUGALPN-303 solution for injection in pre-filled syringe

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Phase 2: Percent change in total immunoglobulin G (IgG) [Time Frame: Baseline and At Week 12], Phase 2 and LTE: Safety and tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)	—

Outcome results

None listed

Source: EU CTIS · Data processed: May 30, 2026